In the latest installment of CBC Health’s Second Opinion, a review of health and medical science news, we reflect on the stories that made headlines in 2025. From breakthroughs in post-partum depression treatment to innovative genetic therapies for rare diseases, the year was marked by significant advancements in healthcare. Looking ahead to 2026, the CBC Health Unit anticipates key developments in various areas, such as improving access to family doctors, changes in cancer screening protocols, addressing vaccine misinformation, exploring new applications for medications like Ozempic and Wegovy, and tackling the evolving challenges posed by the toxic drug crisis.
One notable success story from 2025 was the initiative taken by the city of Colwood in British Columbia to address the shortage of family doctors. By offering doctors municipal employment with benefits like stable salaries and pensions, Colwood managed to attract physicians and establish a new clinic to serve the community. This innovative approach has garnered attention nationwide, inspiring similar efforts in other regions as a potential solution to the ongoing healthcare provider scarcity.
In the realm of cancer screening, Canadians can expect new guidelines in 2026 following a comprehensive review of the Canadian Task Force on Preventive Health Care. This review was prompted by concerns over outdated recommendations and delays in guideline updates. The upcoming changes aim to enhance the effectiveness and relevance of cancer screening practices across the country, ensuring that Canadians receive the most current and evidence-based guidance for early detection and prevention.
On the global front, the resurgence of vaccine-preventable diseases has raised alarms, with Canada losing its measles elimination status amid declining vaccination rates. Vaccine hesitancy, misinformation, and political controversies have contributed to this concerning trend, highlighting the importance of maintaining public trust in immunization programs. As countries strive to combat the spread of preventable illnesses, the need for coordinated efforts to promote vaccination and combat misinformation remains paramount.
In the realm of pharmaceuticals, the upcoming expiration of the patent for Ozempic in Canada opens the door for the introduction of generic versions of the medication, potentially leading to more affordable options for diabetes and obesity treatment. The availability of generic alternatives could significantly reduce the cost burden for patients currently using Ozempic, offering a broader range of treatment options in the market.
Lastly, while progress has been made in addressing substance-related harms, challenges persist in combating the illegal drug supply. Medical authorities highlight the evolving nature of the drug crisis, with new compounds posing unique risks and complexities for overdose reversal efforts. Despite some improvements in reducing fatalities, the ever-changing landscape of illicit drugs underscores the ongoing need for vigilance and innovative strategies to mitigate harm and save lives.
As we navigate the complex landscape of healthcare in 2026, these key developments will shape the future of medical science and public health, highlighting the importance of adaptability, collaboration, and evidence-based decision-making in addressing emerging challenges and opportunities.
